Patents by Inventor Ann E. Tollefson

Ann E. Tollefson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Replication-competent anti-cancer vectors
    Patent number: 8658610
    Abstract: Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: February 25, 2014
    Assignee: Saint Louis University
    Inventors: William S. M. Wold, Karoly Toth, Konstantin Doronin, Ann E. Tollefson
  • REPLICATION-COMPETENT ANTI-CANCER VECTORS
    Publication number: 20100034776
    Abstract: Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.
    Type: Application
    Filed: September 16, 2009
    Publication date: February 11, 2010
    Inventors: William S.M. Wold, Karoly Toth, Konstantin Doronin, Ann E. Tollefson
  • Replication-competent anti-cancer vectors
    Patent number: 7608255
    Abstract: Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.
    Type: Grant
    Filed: October 13, 2005
    Date of Patent: October 27, 2009
    Assignee: Saint Louis University
    Inventors: William S. M. Wold, Karoly Toth, Konstantin Doronin, Ann E. Tollefson
  • Replication-competent anti-cancer vectors
    Patent number: 7589069
    Abstract: Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: September 15, 2009
    Assignee: Saint Louis University
    Inventors: William S. M. Wold, Karoly Toth, Konstantin Doronin, Ann E. Tollefson
  • Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
    Patent number: 6627190
    Abstract: Novel adenovirus vectors which overexpress an adenovirus death protein and which are replication-competent in and, preferably, replication-restricted to cells expressing telomerase. One embodiment provides for efficient destruction and removal of viral-infected host cells expressing telomerase. Still further, another embodiment provides for additional restriction and safety by disrupting E1A's ability to bind p300 and/or members of the Rb family members. Compositions of the novel vectors and methods for promoting death of cells expressing telomerase with these vectors are also disclosed.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: September 30, 2003
    Assignee: Saint Louis University
    Inventors: William S. M. Wold, Karoly Toth, Konstantin Doronin, Ann E. Tollefson, Mohan Kuppuswamy
  • Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
    Publication number: 20020028785
    Abstract: Novel adenovirus vectors which overexpress an adenovirus death protein and which are replication-competent in and, preferably, replication-restricted to cells expressing telomerase. One embodiment provides for efficient destruction and removal of viral-infected host cells expressing telomerase. Still further, another embodiment provides for additional restriction and safety by disrupting E1A's ability to bind p300 and/or members of the Rb family members. Compositions of the novel vectors and methods for promoting death of cells expressing telomerase with these vectors are also disclosed.
    Type: Application
    Filed: September 19, 2001
    Publication date: March 7, 2002
    Applicant: Saint Louis University
    Inventors: William S.M. Wold, Karoly Toth, Ann E. Tollefson, Mohan Kuppuswamy